Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

@article{Sudlow2009ThienopyridineDV,
  title={Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.},
  author={C. Sudlow and Gillian Mason and James B Maurice and C. Wedderburn and G. Hankey},
  journal={The Cochrane database of systematic reviews},
  year={2009},
  volume={4},
  pages={
          CD001246
        }
}
BACKGROUND Aspirin is the most widely studied and prescribed antiplatelet agent for preventing serious vascular events, reducing the odds of such events among high vascular risk patients by about a quarter. Thienopyridine derivatives inhibit platelet activation by a different mechanism and so may be more effective. OBJECTIVES To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke… Expand
33 Citations
Antiplatelet agents for intermittent claudication.
  • 51
Antiplatelet therapy in cerebrovascular disorders.
  • 9
Antiplatelets in stroke prevention.
  • 11
  • PDF
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
  • 9
  • PDF
...
1
2
3
4
...

References

SHOWING 1-10 OF 60 REFERENCES
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
  • 65
  • PDF
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
  • 558
  • PDF
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
  • 1,857
  • PDF
...
1
2
3
4
5
...